Tenofovir-associated acute and chronic kidney disease: A case of multiple drug interactions

Clinical Infectious Diseases

Volumn 42, Issue 2, 2006, Pages 283-290

  Zimmermann, Anthony E ^a,b   Pizzoferrato, Thomas ^b   Bedford, John ^c   Morris, Anne ^c,d   Hoffman, Robert ^b   Braden, Gregory ^c,d  

^a MASSACHUSETTS COLLEGE OF PHARMACY AND HEALTH SCIENCES   (United States)

^b Mercy Medical Center   (United States)

^c BAYSTATE MEDICAL CENTER   (United States)

^d TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ADEFOVIR; AMPRENAVIR; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ANTIRETROVIRUS AGENT; ATAZANAVIR; ATORVASTATIN; CIDOFOVIR; COTRIMOXAZOLE; DELAVIRDINE; DIDANOSINE; EFAVIRENZ; FENOFIBRATE; FLUCONAZOLE; LAMIVUDINE; LOPINAVIR PLUS RITONAVIR; METFORMIN; NEVIRAPINE; OMEPRAZOLE; PEGINTERFERON; PRAVASTATIN; PROTEINASE INHIBITOR; RIBAVIRIN; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; TENOFOVIR DISOPROXIL; UNINDEXED DRUG; ZALCITABINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ACUTE KIDNEY FAILURE; ACUTE KIDNEY TUBULE NECROSIS; ADULT; CHRONIC KIDNEY FAILURE; CLINICAL ARTICLE; CREATININE BLOOD LEVEL; DIABETES MELLITUS; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG METABOLISM; FANCONI RENOTUBULAR SYNDROME; GLOMERULUS FILTRATION RATE; HEPATITIS B; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN TISSUE; KIDNEY FUNCTION; MALE; NEPHROGENIC DIABETES INSIPIDUS; NEPHROTOXICITY; PATIENT MONITORING; PRIORITY JOURNAL; REVIEW; TREATMENT OUTCOME; VIRUS INFECTION;

ADENINE; AGED; ANTI-HIV AGENTS; CREATININE; DRUG INTERACTIONS; HUMANS; KIDNEY FAILURE; MALE; MIDDLE AGED; PHOSPHONIC ACIDS; RISK FACTORS;

EID: 30144434319     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/499048     Document Type: Review

References (28)

1. Tanji N, Tanji K, Kambham N, et al. Adefovir nephrotoxicity: Possible role of mitochondrial DNA depletion. Hum Pathol 2001:32:734-40.
2. Vandercam B, Moreau M, Goffin E, et al. Cidofovir-induced end-stage renal failure. Clin Infect Dis 1999; 29:948-9.
3. Fisher EJ, Chaloner K, Cohn DL, et al. The safety and efficacy of adefovir dipivoxil in patients with advanced HIV disease: a randomized, placebo-controlled trial. AIDS 2001; 15:1695-700.
4. Bochet MV, Jacquiaud C, Valantin MA, et al. Renal insufficiency induced by ritonavir in HIV-infected patients. Am J Med 1998; 105:457.
5. Reiter WJ, Schon-Pernerstorfer H, Dorfinger K, et al. Frequency of urolithiasis in individuals seropositive for human immunodeficiency virus treated with indinavir is higher than previously assumed. J Urol 1999;161:1082-4.
6. Creput C, Gonzalez-Canali G, Hill G, et al. Renal lesions in HIV-1 positive patient treated with tenofovir. AIDS 2003; 17:935-7.
7. Coca S, Perazella MA. Acute renal failure associated with tenofovir: evidence of drug-induced nephrotoxicity. Am J Med Sci 2002; 324:342.
8. Dupont C, Meier F, Loupy A, et al. Acute renal failure and tenofovir: 2 new cases [abstract 694]. In: Program and abstracts of the 2nd International AIDS Society Conference on HIV Pathogenesis and Treatment (Paris). Stockholm: International AIDS Society, 2003.
9. Caspar G, Monereo A, Garcia-Reyne A, et al. Fanconi syndrome and acute renal failure in a patient treated with tenofovir: a call for caution. AIDS 2004; 18:351-2.
10. Karras A, Lafaurie M, Furco A, et al. Tenofovir-related nephrotoxicity in human immunodeficiency virus-infected patients: three cases of renal failure, Fanconi syndrome and nephrogenic diabetes insipidus. Clin Infect Dis 2003; 36:1070-3.
11. Peyriere H, Reynes I, Rouanet I, et al. Renal tubular dysfunction associated with tenofovir therapy. JAIDS 2004; 35:269-73.
12. Rollot F, Nazal E, Chauvelot-Moachon L, et al. Tenofovir-related Fanconi syndrome with nephrogenic diabetes insipidus in a patient with acquired immunodeficiency syndrome: the role of lopinavir-ritonavirdidanosine. Clin Infect Dis 2003;37:e174-6.
13. Schaaf B, Aries SP, Kramme E, et al. Acute renal failure associate with tenofovir treatment in a patient with acquired immunodeficiency syndrome. Clin Infect Dis 2003;37:e41-3.
14. Verhelst D, Monge M, Meynard JL, et al. Fanconi syndrome and renal failure induced by tenofovir: a first case report. Am J Kidney Dis 2002;40:1331-3.
15. Izzedine H, Launay-Vacher V, Isnard-Bagnis C, et al. Drug-induced Fanconi's syndrome. Am J Kid Dis 2003; 41:292-309.
16. Rifkin BS, Perazella MA. Tenofovir-associated nephrotoxity: Fanconi syndrome and renal failure. Am J Med 2004; 117:282-4.
17. Cihlar T, Ho ES, Lin DC, et al. Human renal organic anion transporter 1 (hOAT1) and its role in the nephrotoxicity of antiviral nucleotide analogs. Nucleosides Nucleotides Nucleic Acids 2001; 20:641-8.
18. Birkus G, Hitchcock MJM, Cihlar T. Assessment of mitochondrial toxicity in human cells treated with tenofovir: comparison with other nucleoside reverse transcriptase inhibitors. Antimicrob Agents Chemother 2002;46(3):716-23.
19. Viread (tenofovir disoproxil fumarate) [package insert]. Foster City, CA; Gilead Sciences, 2005.
20. US Food and Drug Administration. FDA report: background package for NDA 21-356: Viread. 2001. Available at http://www.fda.gov/cder/approval/v.htm. Accessed September 2004.
21. Schooley RT, Ruane P, Myers RA, et al. Tenofovir DF in antiretroviral-experienced patients: results from a 48-week, randomized, double-blind study. AIDS 2002; 16:1257-63.
22. Knupp CA, Shyu WC, Dolirf R, et al. Pharmacokinetics of didanosine in patients with acquired immunodeficiency syndrome or acquired immunodeficiency syndrome-related complex. Clin Pharmacol Ther 1991; 49:523-35.
23. Knupp CA, Hak LJ, Coakley DF, et al. Disposition of didanosine in HIV-seropositive patients with normal renal function or chronic renal failure: influence of hemodialysis and continuous ambulatory peritoneal dialysis. Clin Pharmacol Ther 1996; 60:535-42.
24. Crowther MA, Callaghan W, Hodsman AB, et al. Dideoxyinosine-associated nephrotoxicity. AIDS 1993; 7:131-2.
25. Perloff ES, Duan SX, Skolnik PR, et al. Atazanavir: effects on P-gp transport and CYP3A metabolism in vitro. Drug Metab Dispos 2005;33(6):764-70.
26. Boffito M, Kurowski M, Kruse G, et al. Atazanavir enhances saquinavir hard-gel concentrations in a ritonavir-boosted once-daily regimen. AIDS 2004; 18:1291-7.
27. Taburet AM, Piketty C, Chazallon C, et al. Interactions between atazanavir-ritonavir and tenofovir in heavily pretreated human immunodeficiency virus-infected patients. Antimicrob Agents Chemother 2004; 48:2091-6.
28. Guttmann H, Fricker G, Drewe J, et al. Interactions of HIV protease inhibitors with ATP-dependent drug export proteins. Molecul Pharmacol 1999; 56:383-9.